Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02801903 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris
A Phase 1 study, sponsored by Novan.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02801903 is a Phase 1 study that has completed, run by Novan. The registered enrollment target is 18 participants.
The verdict
NCT02801903, a Phase 1 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
A Phase 1, Single-center, Open-label, Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents with Moderate to Severe Acne Vulgaris
Interventions
- DRUG SB204 4%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-06-07 |
| Est. Completion | 2016-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02801903
The ClinicalTrials.gov registry entry for NCT02801903 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB204 4% is the first listed.
NCT02801903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02801903 about?
NCT02801903 is a clinical study titled "Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris". A Phase 1, Single-center, Open-label, Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents with Moderate to Severe Acne Vulgaris
What is the current status of trial NCT02801903?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-06-07. Estimated completion is 2016-08-25.
What interventions are being tested in trial NCT02801903?
The interventions under investigation include: SB204 4% (DRUG).
Who is sponsoring clinical trial NCT02801903?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.